27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The objective of the review is to assess the effect of metformin on the risk, progression and severity of Alzheimer's disease and other forms of dementia, as well as any measures of cognitive performance or impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The results of epidemiological and pathophysiological studies suggest that type 2 diabetes mellitus (T2DM) may predispose to Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As patients lose cognitive function, they lose autonomy and increasingly use fiscal, social, and medical resources. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The incidence of dementia is expected to double in the next 20 years and will contribute to heavy social and economic burden. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A significant body of evidence supports the protective role of exercise training (ET) in cardiovascular diseases, skeletal muscle dystrophies, several types of cancer, Alzheimer disease or even in the recovery of spinal cord injury. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Increased age is associated with normative declines in both sleep and cognitive functioning. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The endogenous circadian rhythms are one of the cardinal processes that control sleep. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a significant public health concern. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The nerve center responsible for controlling our circadian rhythm is located in a cluster of cells known as the suprachiasmatic nucleus in the hypothalamus. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is increasing in prevalence and has a significant impact on caregivers and the healthcare system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sleep disturbances such as insomnia, hypersomnia, and circadian rhythm disturbance are common in normal elderly and Alzheimer's disease (AD) patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), which accounts for most of the dementia cases, is, aside from cognitive deterioration, often characterized by the presence of non-cognitive symptoms. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common cause of dementia and currently there are no effective disease-modifying treatments available. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hearing loss can be caused by a number of different pathological conditions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolic syndrome (MetS) is a common and complex disorder combining hypertension, obesity, dyslipidemia, and insulin resistance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by cognitive dysfunction and progressive neurodegeneration. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Large artery stiffness is a frequent condition that arises with ageing, and is accelerated by the presence of co-morbidities like hypertension, obesity and diabetes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive reserve beneficially affects cognitive performance, even into advanced age. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article covers current research on the relationship between depression and cognitive impairment in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article appraises several facets of the linkage between depression and cognitive impairment, including dementia, mild cognitive impairment, and vascular dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Use of omega-3 in psychiatric practice is on the rise. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia and osteoporosis are multifaceted disease processes with similar epidemiology and a marked increase in prevalence in elderly populations. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Activation of innate immunity and the assembly of microglial cells at sites of Alzheimer disease pathology has long been regarded as bystander phenomenon, which does not actively contribute to disease pathogenesis and progression. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neuroinflammatory responses in Alzheimer's disease (AD) are complex and not fully understood. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purposes of this review were as follows: first, to provide an overview of the gut microbiota and its interactions with the gut and the central nervous system (the microbiota-gut-brain axis) in health, second, to review the relevance of this axis to the pathogenesis of neurodegenerative diseases, such as Parkinson's disease, and, finally, to assess the potential for microbiota-targeted therapies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →